REGN insider filings

REGENERON PHARMACEUTICALS, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-18. Screen REGN transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 16 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
SING GEORGE L — Director2—13 legs · 23,129 sh · $22,294,3034
MURPHY ANDREW J — Co-Chief Scientific Officer3—43 legs · 9,158 sh · $8,003,7127
POON CHRISTINE A — Director1—6 legs · 7,830 sh · $7,587,9582
Zoghbi Huda Y — Director1—2 legs · 7,439 sh · $7,219,2742
LAROSA JOSEPH J — EVP General Counsel and Secret1—2 legs · 4,466 sh · $4,311,8903
Pitofsky Jason — SVP Controller1—8 legs · 4,062 sh · $3,827,1596
McCourt Marion — EVP Commercial3—16 legs · 4,044 sh · $3,530,157—
BROWN MICHAEL S — Director1—1 leg · 1,929 sh · $1,687,8752
Guarini Kathryn — Director2—2 legs · 800 sh · $700,0004
Fenimore Christopher R. — EVP Finance CFO1——4

Recent insider filings — REGENERON PHARMACEUTICALS, INC.

FiledFormInsiderReported transactionsSource
2026-11-184SING GEORGE L — DirectorSale (S): 1,000 @ $960.26 · Sale (S): 176 @ $956.96 · Sale (S): 359 @ $957.49 · Sale (S): 465 @ $958.11EDGAR
2026-11-184MURPHY ANDREW J — Co-Chief Scientific OfficerOption exercise (M): 17,000 @ $381.92 · Tax withholding (F): 11,989 @ $960.02 · Sale (S): 93 @ $949.69 · Sale (S): 74 @ $950.61 · Sale (S): 298 @ $951.75 · Sale (S): 220 @ $952.75 · +13 moreEDGAR
2026-11-184McCourt Marion — EVP CommercialSale (S): 44 @ $952.79 · Sale (S): 59 @ $954.46 · Sale (S): 30 @ $955.51 · Sale (S): 22 @ $956.01 · Sale (S): 44 @ $958.47 · Sale (S): 66 @ $959.46 · +7 moreEDGAR
2026-11-064Pitofsky Jason — SVP ControllerOption exercise (M): 1,500 @ $726.53 · Option exercise (M): 1,478 @ $644.54 · Option exercise (M): 905 @ $492 · Sale (S): 439 @ $939.57 · Sale (S): 575 @ $940.46 · Sale (S): 982 @ $941.58 · +8 moreEDGAR
2026-11-054MURPHY ANDREW J — Co-Chief Scientific OfficerGift (G): 1,054 @ $0EDGAR
2026-11-054Zoghbi Huda Y — DirectorOption exercise (M): 7,439 @ $380.95 · Sale (S): 6,939 @ $970.42 · Sale (S): 500 @ $971.06 · Option exercise (M): 7,439 (derivative) @ $0EDGAR
2026-11-044SING GEORGE L — DirectorOption exercise (M): 7,830 @ $376.69 · Option exercise (M): 7,439 @ $380.95 · Sale (S): 1,224 @ $960.57 · Sale (S): 540 @ $961.85 · Sale (S): 2,522 @ $962.61 · Sale (S): 4,338 @ $963.47 · +7 moreEDGAR
2026-11-044Fenimore Christopher R. — EVP Finance CFOOption exercise (M): 6,000 @ $381.92 · Tax withholding (F): 4,243 @ $950.50 · Gift (G): 15 @ $0 · Option exercise (M): 6,000 (derivative) @ $0EDGAR
2026-11-044POON CHRISTINE A — DirectorOption exercise (M): 7,830 @ $376.69 · Sale (S): 218 @ $966.74 · Sale (S): 772 @ $967.38 · Sale (S): 2,499 @ $968.58 · Sale (S): 3,203 @ $969.50 · Sale (S): 937 @ $970.51 · +2 moreEDGAR
2026-11-044LAROSA JOSEPH J — EVP General Counsel and SecretOption exercise (M): 12,283 @ $381.92 · Tax withholding (F): 8,686 @ $950.50 · Sale (S): 3,939 @ $965.41 · Sale (S): 527 @ $966.11 · Option exercise (M): 12,283 (derivative) @ $0EDGAR
2026-11-034Guarini Kathryn — DirectorOption exercise (M): 400 @ $719.37 · Sale (S): 400 @ $900 · Option exercise (M): 400 (derivative) @ $0EDGAR
2026-11-034BROWN MICHAEL S — DirectorOption exercise (M): 1,929 @ $725.89 · Sale (S): 1,929 @ $875 · Option exercise (M): 1,929 (derivative) @ $0EDGAR
2026-11-034McCourt Marion — EVP CommercialSale (S): 1,132 @ $869.43EDGAR
2026-10-154MURPHY ANDREW J — Co-Chief Scientific OfficerOption exercise (M): 17,000 @ $381.92 · Tax withholding (F): 12,853 @ $754.58 · Sale (S): 6 @ $753.76 · Sale (S): 35 @ $755.91 · Sale (S): 16 @ $757.68 · Sale (S): 24 @ $758.16 · +24 moreEDGAR
2026-09-034Guarini Kathryn — DirectorOption exercise (M): 400 @ $719.37 · Sale (S): 400 @ $850 · Option exercise (M): 400 (derivative) @ $0EDGAR
2026-09-034McCourt Marion — EVP CommercialSale (S): 1,215 @ $850 · Sale (S): 1,131 @ $857.39EDGAR
2026-08-214LAROSA JOSEPH J — EVP General Counsel and SecretOption exercise (M): 12,282 @ $381.92 · Tax withholding (F): 9,019 @ $830.15 · Option exercise (M): 12,282 (derivative) @ $0EDGAR
2026-08-204Fenimore Christopher R. — EVP Finance CFOOption exercise (M): 6,283 @ $381.92 · Tax withholding (F): 4,599 @ $813.47 · Option exercise (M): 6,283 (derivative) @ $0EDGAR
2026-08-124Zoghbi Huda Y — DirectorOption exercise (M): 800 @ $376.69 · Sale (S): 800 @ $800 · Option exercise (M): 800 (derivative) @ $0EDGAR
2026-08-124Guarini Kathryn — DirectorOption exercise (M): 400 @ $719.37 · Sale (S): 400 @ $800 · Option exercise (M): 400 (derivative) @ $0EDGAR
2026-07-074RYAN ARTHUR F — DirectorSale (S): 200 @ $650.15EDGAR
2026-05-044RYAN ARTHUR F — DirectorSale (S): 5 @ $701.76 · Sale (S): 15 @ $702.46 · Sale (S): 24 @ $703.46 · Sale (S): 15 @ $704.28 · Sale (S): 14 @ $705.56 · Sale (S): 7 @ $706.74 · +6 moreEDGAR
2026-04-034RYAN ARTHUR F — DirectorSale (S): 1 @ $771.32 · Sale (S): 3 @ $772.76 · Sale (S): 8 @ $773.59 · Sale (S): 8 @ $774.58 · Sale (S): 14 @ $775.58 · Sale (S): 13 @ $776.62 · +3 moreEDGAR
2026-03-034RYAN ARTHUR F — DirectorSale (S): 7 @ $777.46 · Sale (S): 2 @ $778.30 · Sale (S): 5 @ $779.69 · Sale (S): 3 @ $780.69 · Sale (S): 2 @ $781.21 · Sale (S): 2 @ $782.62 · +7 moreEDGAR
2026-02-234Zoghbi Huda Y — DirectorOption exercise (M): 1,638 @ $376.69 · Sale (S): 49 @ $774.68 · Sale (S): 50 @ $775.50 · Sale (S): 53 @ $778.47 · Sale (S): 208 @ $779.55 · Sale (S): 331 @ $780.45 · +7 moreEDGAR
2026-02-114Pitofsky Jason — SVP ControllerOption exercise (M): 1,000 @ $492 · Sale (S): 20 @ $775.95 · Sale (S): 521 @ $776.43 · Sale (S): 391 @ $777.51 · Sale (S): 563 @ $778.35 · Sale (S): 205 @ $779.56 · +7 moreEDGAR
2026-02-114RYAN ARTHUR F — DirectorSale (S): 1 @ $775.63 · Sale (S): 10 @ $776.59 · Sale (S): 57 @ $777.56 · Sale (S): 12 @ $778.53 · Sale (S): 5 @ $779.41 · Sale (S): 1 @ $780.09 · +7 moreEDGAR
2026-01-084Bassler Bonnie L — DirectorOption exercise (M): 1,500 @ $374.12 · Sale (S): 1,500 @ $800 · Option exercise (M): 1,500 (derivative) @ $0EDGAR
2026-01-064Guarini Kathryn — DirectorGrant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-064Bassler Bonnie L — DirectorGrant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-064Zoghbi Huda Y — DirectorGrant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-064Schenkein David P — DirectorGrant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-064Thompson Craig B. — DirectorGrant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-064GOLDSTEIN JOSEPH L — DirectorGrant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-064SING GEORGE L — DirectorGrant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-064COLES N ANTHONY — DirectorGrant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-064POON CHRISTINE A — DirectorGrant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-064RYAN ARTHUR F — DirectorGrant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-064BROWN MICHAEL S — DirectorGrant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-054YANCOPOULOS GEORGE — Bd. Co-Chair, President & CSO, DirectorOption exercise (M): 28,570 @ $0 · Tax withholding (F): 28,570 @ $772.09 · Option exercise (M): 28,570 (derivative) @ $0EDGAR
2026-01-054SCHLEIFER LEONARD S — Bd. Co-Chair, President & CEO, DirectorOption exercise (M): 28,570 @ $0 · Tax withholding (F): 28,570 @ $772.09 · Option exercise (M): 28,570 (derivative) @ $0EDGAR
2025-12-314SING GEORGE L — DirectorOption exercise (M): 9,212 @ $520.01 · Tax withholding (F): 6,188 @ $774.03 · Option exercise (M): 9,212 (derivative) @ $0EDGAR
2025-12-114MURPHY ANDREW J — EVP ResearchTax withholding (F): 4,229 @ $701.51EDGAR
2025-12-114McCourt Marion — EVP CommercialTax withholding (F): 1,021 @ $701.51EDGAR
2025-12-114Van Plew Daniel P — EVP & General Mgr, IndustrialTax withholding (F): 2,552 @ $701.51EDGAR
2025-12-114YANCOPOULOS GEORGE — Bd. Co-Chair, President & CSO, DirectorOption exercise (M): 146,815 @ $555.67 · Tax withholding (F): 131,874 @ $701.51 · Option exercise (M): 146,815 (derivative) @ $0EDGAR
2025-12-114SCHLEIFER LEONARD S — Bd. Co-Chair, President & CEO, DirectorOption exercise (M): 172,723 @ $555.67 · Tax withholding (F): 155,145 @ $701.51 · Option exercise (M): 172,723 (derivative) @ $0EDGAR
2025-12-094McCourt Marion — EVP CommercialGrant/award (A): 2,476 @ $0 · Tax withholding (F): 1,336 @ $712.94 · Grant/award (A): 12,210 (derivative) @ $0EDGAR
2025-12-094Van Plew Daniel P — EVP & General Mgr, IndustrialGrant/award (A): 3,715 @ $0 · Tax withholding (F): 1,906 @ $712.94 · Grant/award (A): 18,315 (derivative) @ $0EDGAR
2025-12-094LAROSA JOSEPH J — EVP General Counsel and SecretGrant/award (A): 2,476 @ $0 · Tax withholding (F): 1,396 @ $712.94 · Grant/award (A): 12,210 (derivative) @ $0EDGAR

Recent 8-K events — REGENERON PHARMACEUTICALS, INC.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-10-308-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-068-K1.01 — Entry into a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
8.01 — Other Events
EDGAR
2026-09-308-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-308-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-068-K2.02 — Results of Operations and Financial ConditionEDGAR
2026-06-178-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-04-298-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-088-K2.02 — Results of Operations and Financial ConditionEDGAR
2026-01-308-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-01-128-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=REGN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs